Conclusions
This economic evaluation concludes that the provision of intravenous
co-amoxiclav following operative vaginal delivery is a cost-effective
intervention, offering improved QOL whilst also reducing overall costs
over a 6-week time period. Prior to this study, existing literature
regarding the cost-effectiveness of this intervention was sparse;
consequently, this study significantly adds to the literature as the
first UK economic evaluation to be conducted for this intervention.
Importantly, we recommend an update to current NICE guidelines, so that
administration of co-amoxiclav following operative vaginal delivery is
viewed as the gold-standard practice. Further research should focus on
identifying and assessing the cost and benefit of alternative
antibiotics against co-amoxiclav